$227.73 5.8 2.6%
Last Trade - 05/03/21
| Market Cap | £95.03bn |
| Enterprise Value | £111.17bn |
| Revenue | £18.37bn |
| Position in Universe | 90th / 6651 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 21,662 | 22,991 | 22,849 | 23,747 | 23,362 | 25,424 | 26,458 | 27,419 | +3.3% | ||
| +27.7 | +12.1 | +11.5 | +14.0 | -0.5 | -4.9 | +37.1 | +9.06 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | October 31, 1986 |
| Public Since | May 1, 1987 |
| No. of Shareholders: | 5,336 |
| No. of Employees: | 24,300 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Dow Jones Composite , Dow Jones Industrial Average , Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 577,566,383 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 Amgen Center Dr, THOUSAND OAKS, 91320-1730, United States |
| Web | http://www.amgen.com |
| Phone | +1 805 4471000 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 05/03/21, shares in Amgen Inc are trading at $227.73, giving the company a market capitalisation of £95.03bn. This share price information is delayed by 15 minutes.
Shares in Amgen Inc are currently trading at $227.73 and the price has moved by 7.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Amgen Inc price has moved by -15.32% over the past year.
Of the analysts with advisory recommendations for Amgen Inc, there are there are currently 7 "buy" , 14 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Amgen Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Amgen Inc is scheduled to issue upcoming financial results on the following dates:
The Amgen Inc dividend yield is 2.81% based on the trailing twelve month period.
Last year, Amgen Inc paid a total dividend of 6.4, and it currently has a trailing dividend yield of 2.81%. Looking ahead, shares in Amgen Inc are due to go ex-dividend on 2021-05-14 and the next dividend pay date is 2021-03-08.
Amgen Inc are due to go ex-dividend on 2021-05-14 and the next dividend pay date is 2021-03-08. The historic dividend yield on Amgen Inc shares is currently 2.81%.
To buy shares in Amgen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Amgen Inc are currently trading at $227.73, giving the company a market capitalisation of £95.03bn.
Here are the trading details for Amgen Inc:
Based on an overall assessment of its quality, value and momentum, Amgen Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Amgen Inc are currently priced at $227.73. At that level they are trading at 11.62% discount to the analyst consensus target price of 0.00.
Analysts covering Amgen Inc currently have a consensus Earnings Per Share (EPS) forecast of 16.881 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amgen Inc. Over the past six months, the relative strength of its shares against the market has been -18.94%. At the current price of $227.73, shares in Amgen Inc are trading at -3.92% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Amgen Inc PE ratio based on its reported earnings over the past 12 months is 18.5. The shares are currently trading at $227.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Amgen Inc's management team is headed by:
Here are the top five shareholders of Amgen Inc based on the size of their shareholding:
